FDA Approving Complex Generics Pre-ANDA Meeting Requests At Higher Rates
Uptrend Could Signal Surge In Complex-Generic Approvals
Approval rates for complex-drug pre-ANDA meeting requests are climbing. FDA’s hope is that the meetings will hasten approvals of these hard-to-manufacture generics, which could put a dent in US healthcare costs.
